What happened
ClinicalTrials.gov registry update for CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus
SourceClinicalTrials.govclinical updateBiotech
CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus
Clinical/translation signal: CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus
Factual summary
Why it matters
Clinical trial registry updates are translation signals, not commercialization claims by themselves.
SourceClinicalTrials.govLimitations
ClinicalTrials.gov status does not prove product approval, licensing, revenue, or market adoption.
SourceClinicalTrials.govLinked output
CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosusclinical trialPeople
No reviewed person relationship is attached to this event.
Organizations
Topics
No reviewed topic relationship is attached to this event.
Problems
No reviewed problem relationship is attached to this event.
Relationship evidence
CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus
CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (NCT07659704)
Timeline
- clinical updateCD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus